GI Innovation Inc
KOSDAQ:358570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GI Innovation Inc
Other Current Liabilities
GI Innovation Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Other Current Liabilities
₩3.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Other Current Liabilities
₩821B
|
CAGR 3-Years
24%
|
CAGR 5-Years
22%
|
CAGR 10-Years
24%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Other Current Liabilities
₩5.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Other Current Liabilities
₩131.5B
|
CAGR 3-Years
145%
|
CAGR 5-Years
79%
|
CAGR 10-Years
81%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Other Current Liabilities
₩67.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Other Current Liabilities
₩3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Other Current Liabilities?
Other Current Liabilities
3.4B
KRW
Based on the financial report for Dec 31, 2024, GI Innovation Inc's Other Current Liabilities amounts to 3.4B KRW.
What is GI Innovation Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
-7%
Over the last year, the Other Current Liabilities growth was -18%. The average annual Other Current Liabilities growth rates for GI Innovation Inc have been -7% over the past three years .
